Core Viewpoint - The Schall Law Firm is investigating Backblaze, Inc. for potential violations of securities laws following a significant drop in its stock price due to a negative report from Morpheus Research [1][2]. Group 1: Investigation Details - The investigation centers on whether Backblaze made false or misleading statements and failed to disclose important information to investors [2]. - The company's stock experienced a sharp decline attributed to a critical report from Morpheus Research, which highlighted alleged financial missteps and questionable practices since its IPO in November 2021 [2]. Group 2: Allegations from the Report - The Morpheus Research report claims that Backblaze engaged in questionable accounting practices, including financial manipulations and inflated forecasts to meet audit thresholds [2].

Core Viewpoint - The Schall Law Firm is investigating claims against Affirm Holdings, Inc. for potential violations of securities laws following a significant drop in its stock price after losing a major partnership with Walmart to rival Klarna [1][2]. Group 1: Company Overview - Affirm Holdings, Inc. is a fintech company that offers Buy Now, Pay Later (BNPL) services [2]. - The company has recently faced challenges due to competition, particularly from Klarna, which has taken over as Walmart's exclusive BNPL provider [2]. Group 2: Stock Performance - Following the announcement of Klarna replacing Affirm as Walmart's BNPL provider, Affirm's shares fell by more than 12.7% the next day [2]. Group 3: Legal Investigation - The investigation by the Schall Law Firm focuses on whether Affirm made false or misleading statements or failed to disclose important information to investors [2].

Core Viewpoint - The Schall Law Firm is investigating Aldeyra Therapeutics, Inc. for potential violations of securities laws following a significant drop in share price after the FDA issued a Complete Response Letter regarding the company's drug reproxalap [1][2]. Group 1: Investigation Details - The investigation centers on whether Aldeyra made false or misleading statements or failed to disclose critical information to investors [2]. - On April 3, 2025, Aldeyra announced that the FDA's Complete Response Letter indicated that the NDA for reproxalap "failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes" [2]. - Despite Aldeyra's claims of "uniquely supportive" clinical trial data, the FDA expressed concerns regarding the trial data submitted as part of the NDA [2]. Group 2: Market Impact - Following the FDA's announcement, Aldeyra's shares plummeted by nearly 75% during trading on the same day [2].

Core Viewpoint - The Schall Law Firm is investigating Adverum Biotechnologies, Inc. for potential violations of securities laws related to misleading financial statements and disclosures [1][2]. Group 1: Investigation Details - The investigation centers on whether Adverum made false or misleading statements and failed to disclose critical information to investors [2]. - Adverum announced in an SEC filing on March 31, 2025, that certain previously issued financial statements should no longer be relied upon due to non-cash errors in accounting for tenant improvement allowances related to an operating lease in North Carolina [2]. - The company plans to restate its financial statements for the years ended December 31, 2022, and 2023, as well as unaudited quarterly financial information for 2023 and 2024 [2]. - Following this announcement, Adverum's shares dropped by over 12% on April 1, 2025 [2]. Group 2: Shareholder Rights - The Schall Law Firm encourages shareholders who suffered losses to participate in the investigation and offers free consultations regarding their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Core Viewpoint - A class action lawsuit has been filed against Alarum Technologies Ltd. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its customer engagements and revenue growth [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Alarum's securities between March 14, 2024, and August 26, 2024, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Alarum - The complaint alleges that Alarum failed to retain and expand customer engagements as effectively as claimed, impacting its ability to generate consistent revenue growth [4]. - The company's public statements during the class period are described as false and materially misleading, leading to investor damages when the truth was revealed [4].

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. for alleged violations of securities laws, specifically related to misleading statements made during a secondary stock offering and a proxy statement regarding a merger with AbbVie Inc. [1][5] Group 1: Lawsuit Details - The lawsuit targets investors who purchased shares between October 11, 2023, and August 1, 2024, or held shares as of January 8, 2024, and were entitled to vote on the merger [2] - The class has not yet been certified, meaning potential class members are not currently represented by an attorney [4] Group 2: Allegations Against Cerevel - Cerevel is accused of making false and misleading statements regarding its secondary stock offering on October 16, 2023, and its proxy statement on January 18, 2024, related to AbbVie's acquisition at $45 per share [5] - The secondary stock offering was allegedly organized by Bain and Pfizer to increase Bain's investment at a discounted price, anticipating AbbVie's undisclosed acquisition plan [5] - The acquisition plan was publicly announced just 51 days after the secondary offering, at a price nearly double the offering price, leading to investor damages when the truth emerged [5]

LOS ANGELES, April 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DuPont de Nemours, Inc. ("DuPont" or "the Company") (NYSE: DD) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. DuPont is the subject Wall Street Journal article published on April 4, 2025, t ...

Core Viewpoint - The Schall Law Firm is investigating Valneva SE for potential violations of securities laws related to misleading statements and undisclosed information concerning its chikungunya virus vaccine, IXCHIQ [1][2]. Group 1: Investigation Details - The investigation centers on whether Valneva issued false or misleading statements or failed to disclose critical information to investors [2]. - A CDC notice dated February 25, 2025, indicates an investigation into five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ among individuals aged 65 and older [2]. - Following the CDC notice, Valneva's American Depositary Receipt (ADR) price dropped by over 13.5% in subsequent trading sessions [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who have experienced losses are encouraged to contact the firm for a free discussion of their rights [3].

Group 1 - The Schall Law Firm has initiated a class action lawsuit against enCore Energy Corp for violations of the Securities Exchange Act of 1934 [1][4] - The lawsuit pertains to investors who purchased enCore's securities between March 28, 2024, and March 2, 2025, and encourages them to contact the firm before May 13, 2025 [2][3] - The complaint alleges that enCore made false and misleading statements regarding its financial performance, specifically citing a material weakness in internal controls over financial reporting [4] Group 2 - The company attributed its weak performance in fiscal year 2024 to an ineffective control environment, which led to ineffective risk assessment and monitoring activities [4] - The public statements made by enCore during the class period are claimed to be false and materially misleading, resulting in investor damages when the truth was revealed [4]

Core Viewpoint - A class action lawsuit has been filed against Monolithic Power Systems, Inc. for alleged violations of securities laws due to false and misleading statements regarding the performance and quality of its products, which negatively impacted Nvidia's products [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to securities purchased between February 8, 2024, and November 8, 2024, and investors are encouraged to contact the Schall Law Firm before April 7, 2025, to participate [2]. - The complaint alleges that Monolithic Power's voltage regulator modules and other products exhibited significant performance weaknesses and quality control failures [4]. Group 2: Impact on Relationships - The company's failure to address known issues with its products severely damaged its relationship with Nvidia, leading to materially misleading public statements throughout the class period [4]. Group 3: Investor Actions - Investors who suffered losses are invited to join the case to recover their damages, with the Schall Law Firm specializing in securities class action lawsuits [5].